core

BPC-157

Repair peptide for stalled tendons, gut lining, and slow healing, not a painkiller.

Tissue repair / gastric-derived pentadecapeptide

Research / compounded in most jurisdictions. Not FDA-approved as a finished drug for injury or gut indications.

15-amino-acid fragment from human gastric juice (Body Protection Compound). Acid-stable enough that oral use is discussed for gut applications. Short plasma half-life (<30 minutes) with longer tissue signaling (VEGF / angiogenesis, growth-factor and nitric-oxide pathways, cell migration).

Common-practice ranges, not a personal dose

Quick-reference (Vol 1 Ch.1 arsenal)

250 to 500 mcg twice daily for gut, tendon, ligament, and muscle repair.

VOL1 · Chapter 1 · p.12

Systemic SC / IM (Vol 1 Ch.4)

Standard 200 to 500 µg daily, split into 1 to 2 injections. Duration 2 to 4 weeks acute, 6 to 8 weeks chronic. Rotate abdomen and thighs. Start 200 to 250 µg.

VOL1 · Chapter 4 · p.45 to 46

Localized peri-lesional (Vol 1 Ch.4)

100 to 200 µg per injection, 2 to 3 times weekly, 4 to 6 weeks, into or around target tissue.

VOL1 · Chapter 4 · p.45

Oral GI focus (Vol 1 Ch.4)

500 µg to 2 mg daily on an empty stomach, 4 to 8 weeks, capsule or oral solution (higher because of partial absorption).

VOL1 · Chapter 4 · p.46

Practical daily range used in Vol 2 protocols

250 to 500 mcg/day SC once daily or divided BID. Localized injury 250 to 500 mcg/day near (not into) tissue. GI: 250 to 500 mcg/day oral or SC. Clinical note: going above 500 to 750 mcg/day rarely helps and may rebound inflammation.

VOL2 · Chapter 4 · p.25 to 26

Cycle / washout. Vol 2: typical 4 to 6 weeks, up to 8 weeks chronic, washout 2 to 4 weeks. Re-cycle only if structural recovery is incomplete. If plateaued, do not escalate dose, reassess rehab, inflammation, or stacking.

  • First-line painkiller instead of rehab
  • Cosmetic or vague wellness without a repair target
  • Active malignancy (theoretical angiogenesis concern)
  • Pregnancy / lactation (no safety data)
Flagged in the books: Active malignancy (angiogenesis theory) · Pregnancy / lactation · Acute untreated severe infection · Using as a substitute for rest, loading, or surgery when those are required

Sources: Vol 1 Ch.1 pp.12 to 13 · Vol 1 Ch.4 pp.43 to 55 · Vol 2 Ch.4 pp.21 to 28